When is the next significant data read‑out or milestone (e.g., efficacy results from the GOBLET study) that could further impact the company’s market valuation?

When to expect the next market‑moving catalyst

The GOBLET study is the only ongoing Phase 2/3 Pelareorep trial that involves a gastrointestinal‑cancer cohort. The company has just disclosed updated safety data that now includes >300 GI patients, many of whom are from GOBLET. In oncology data‑release cycles, safety updates normally precede the primary efficacy read‑out, which is typically presented at a disease‑specific conference or submitted to the FDA as a pivotal filing.

Oncolytics has historically timed its first efficacy read‑outs 9‑12 months after safety‑release. The current safety update was made public in early‑June 2024, so the first efficacy milestone for GOBLET is expected in the **Q4 2024 window (mid‑October through December)—most likely at the American Society of Clinical Oncology (ASCO) gastro‑intestional summit or the European Society for Medical Oncology (ESMO) meeting. A definitive efficacy report (overall response rate, progression‑free survival) would constitute the next “significant data read‑out” that could materially swing ONCY’s valuation.

Trading implications

* Short‑term: The market will price in a “data‑dependency” premium right now. With the next efficacy read‑out still 4–6 months away, the stock is likely to remain in a low‑volatility, range‑bound pattern—the daily chart is still respecting the $0.70‑$0.85 support‑resistance band seen since the June safety release.

* Risk‑/reward set‑up: If you are comfortable with the macro‑neutral backdrop (low‑interest‑rate environment, stable biotech capital flows), consider a buy‑the‑dip position near the lower end of the band, with a tight stop just below $0.68. The upside is the anticipated spike on a positive GOBLET efficacy announcement—historically similar reads (e.g., ONCY’s 2022 Phase 2 colorectal data) generated +30‑40 % moves in the first 2‑3 days after release.

* If you are risk‑averse, keep a tight 30‑day stop‑loss given the “all‑eyes‑on‑GOBLET” narrative; a any‑negative safety signal (unlikely given the current profile) would quickly erode the speculative premium.

In short, the primary catalyst to watch is the GOBLET efficacy read‑out slated for Q4 2024, and the market will price ONCY in anticipation of that event. Position accordingly: modest long exposure now, with a clear exit plan before the mid‑term conference, or stay flat if you prefer to avoid the volatility surrounding the upcoming data release.